Genprex regains Nasdaq minimum $2.5M equity compliance; one-year monitoring imposed

Genprex, Inc.

Received Nasdaq Compliance Notice on Jan 7, 2026, reaffirming compliance with Listing Rule 5550(b)(1).
Mandatory Panel Monitor runs through Jan 7, 2027; any deficiency within that period triggers delisting without cure.
If staff finds non-compliance during monitoring, delist determination letter issued; company may request new hearing.
Previously disclosed non-compliance letter from Nasdaq on Aug 19, 2025 has been resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.